Corbus Pharmaceuticals Holdings ((CRBP)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corbus Pharmaceuticals Holdings is conducting a Phase 1/2 clinical study titled A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors. The study aims to evaluate the safety and effectiveness of CRB-601, a monoclonal antibody, in treating patients with advanced solid tumors who have exhausted other treatment options. The significance of this study lies in its potential to offer a new treatment avenue for cancers expressing the avb8 integrin protein.
The intervention being tested is CRB-601, a monoclonal antibody designed to target the avb8 integrin protein, potentially enhancing the effectiveness of existing immunotherapy treatments. The study involves administering CRB-601 alone or in combination with anti-PD-1 therapy to assess its impact on tumor progression and patient safety.
This interventional study is non-randomized with a factorial model, focusing on treatment as its primary purpose. It comprises three parts: dose-escalation, safety lead-in, and dose optimization, with no masking involved.
The study began on September 13, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on May 29, 2025. These dates are crucial for tracking the study’s progress and potential market release.
The ongoing study could significantly impact Corbus Pharmaceuticals’ stock performance, as positive results may boost investor confidence and position the company as a leader in innovative cancer treatments. The study’s progress is particularly relevant in the competitive oncology market, where advancements in treatment options are highly sought after.
The study is currently recruiting, with further details available on the ClinicalTrials portal.